VANCOUVER, BC, December 15, 2025/ – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that Marianne Stanford, PhD, has joined BioVaxys as Scientific Advisor.   Dr Stanford was Vice President of R&D at the former IMV Inc, where she and her team were responsible for the development of the DPX™ vaccine portfolio. This included the study of the unique mechanism of action of the DPX platform and its safety, efficacy, and dosing schedules in preclinical models. Under her leadership, Dr. Stanford’s team also demonstrated that combining DPX, cyclophosphamide and then PD-1 blockade (using antibodies such as pembrolizumab, Merck’s Keytruda™) enhanced immunogenicity and thus efficacy in cancer models.  Dr. Stanford and collaborators have published numerous studies and she is named inventor on multiple patents related to the DPX platform and DPX formulations. This includes patents that explore DPX compositions that express mRNA encoded by the nucleic acid components in targeted cells.

Dr. Stanford was most recently the Chief Scientific Officer at Mara Renewables Corp., where she drove the commercialization of bio-based omega-3 nutrition products for global markets and oversaw teams of scientists across multiple research groups, from discovery science to application research. Prior to this role, Dr. Stanford was the Assistant Scientific Director at the Institute for Infection and Immunity at The Canadian Institutes of Health Research (CIHR), Canada's federal funding agency for health research, where she helped build Canada’s national infectious disease research capacity.  

Dr. Stanford holds a PhD in Microbiology and Immunology from Dalhousie University, complemented by postdoctoral fellowships in viral immunotherapy and oncology.

BioVaxys President and Chief Operating Officer Kenneth Kovan, says "We are pleased to now have the support of Dr. Stanford.  Her deep familiarity with the DPX platform and experience leading the development of DPX formulations for oncology and infectious disease brings significant internal strength to BioVaxys.  We are particularly excited to further her work developing DPX as a delivery platform for mRNA and other polypeptides.”

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX platform, in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

BioVaxys common shares are listed on the CSE under the stock symbol 'BIOV', trade on the Frankfurt Bourse (FRA: 5LB), and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed "James Passin"

Chief Executive Officer

Phone: +1 740 358 0555

Cautionary Statements on Forward Looking Information

This news release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the Offering, including the expected use of proceeds from the Offering. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the risk that the Company does not use the proceeds from the Offering as currently expected. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.

Copyright (c) 2025 TheNewswire - All rights reserved.